Acasti Pharma (NASDAQ: ACST) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Acasti Pharma to related companies based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares Acasti Pharma and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Acasti Pharma||$30,000.00||-$16.77 million||-1.30|
|Acasti Pharma Competitors||$2.03 billion||$140.19 million||-2.18|
Institutional & Insider Ownership
2.3% of Acasti Pharma shares are owned by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.0% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Acasti Pharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Acasti Pharma Competitors||-2,667.92%||-76.75%||-24.48%|
Volatility and Risk
Acasti Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Acasti Pharma’s peers have a beta of 1.17, meaning that their average stock price is 17% more volatile than the S&P 500.
This is a breakdown of recent ratings for Acasti Pharma and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Acasti Pharma Competitors||3731||10927||24910||817||2.56|
Acasti Pharma presently has a consensus price target of $7.00, indicating a potential upside of 607.07%. As a group, “Pharmaceutical preparations” companies have a potential upside of 55.61%. Given Acasti Pharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Acasti Pharma is more favorable than its peers.
Acasti Pharma peers beat Acasti Pharma on 7 of the 13 factors compared.
About Acasti Pharma
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.